Exelixis (EXEL) Invested Capital (2010 - 2017)
Exelixis (EXEL) posted quarterly Invested Capital of $113.3 million for Q1 2017, up 312.18% year-over-year from $27.5 million in Q1 2016, and up 3.87% quarter-over-quarter from $109.1 million in Q4 2016.
Analysis
Exelixis (EXEL) Invested Capital (2010 - 2017) Analysis & Trends
Exelixis' Invested Capital history runs 8 years deep, the most recent figure standing at $113.3 million for Q1 2017.
- In Q1 2017, Invested Capital rose 312.18% year-over-year to $113.3 million; the TTM figure through Dec 2017 stood at $113.3 million (down 41.42% YoY), while the FY2016 annual figure was $109.1 million, changed N/A from the prior year.
- Invested Capital for Q1 2017 stood at $113.3 million, up from $109.1 million in the prior quarter.
- The five-year high for Invested Capital was $113.3 million in Q1 2017, with the low at $450000.0 in Q3 2015.
- The 5-year median for Invested Capital is $27.5 million (2016), against an average of $45.7 million.
- The sharpest annual moves came in 2015 and 2016: Invested Capital tumbled 99.53% in 2015, then surged 6425.56% in 2016.
- Exelixis' Invested Capital stood at $10.0 million in 2013, then soared by 874.49% to $97.4 million in 2014, then slumped by 99.54% to $450000.0 in 2015, then soared by 24149.33% to $109.1 million in 2016, then climbed by 3.87% to $113.3 million in 2017.
- Business Quant data shows EXEL's Invested Capital at $113.3 million in Q1 2017, $109.1 million in Q4 2016, and $29.4 million in Q3 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 29, 2017 | 284.96 Mn |
| Jun 30, 2017 | 148.51 Mn |
| Mar 31, 2017 | 233.10 Mn |
| Dec 30, 2016 | 278.44 Mn |
| Sep 30, 2016 | 141.39 Mn |
| Jun 30, 2016 | -78.63 Mn |
| Mar 31, 2016 | -48.45 Mn |
| Dec 31, 2015 | -60.81 Mn |
| Sep 30, 2015 | 6.22 Mn |
| Jun 30, 2015 | -108.19 Mn |
| Mar 31, 2015 | -62.68 Mn |
| Dec 31, 2014 | 18.51 Mn |
| Sep 30, 2014 | 118.74 Mn |
| Jun 30, 2014 | 178.58 Mn |
| Mar 31, 2014 | 153.09 Mn |
| Dec 31, 2013 | 106.59 Mn |
| Sep 30, 2013 | 225.65 Mn |
| Jun 30, 2013 | 290.01 Mn |
| Mar 31, 2013 | 349.32 Mn |
| Dec 31, 2012 | 333.39 Mn |